Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor Era

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1185-1196

  Ahn, Myung Ju ^a   Lee, Jeeyun ^a   Park, Yun Hee ^a   Ahn, Jin Seok ^a   Ziogas, Argyrios ^b   Zell, Jason A ^b,c   Park, Keunchil ^a   Ignatius Ou, Sai Hong ^b,c  

^a Sungkyunkwan University   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

California Cancer Registry; Epidemiology; Korean ethnicity; Never smokers; Non small cell lung cancer; Prognostic factors; Smoking status; White ethnicity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CHILD; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HUMAN; INFANT; KOREA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION BASED CASE CONTROL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; SURVIVAL RATE; UNITED STATES;

EID: 77955092100     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e2f624     Document Type: Article

References (22)

1. Hechet SS. Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-744.
2. Parkin DM, Bray FJ, Ferlay L, et al. Global cancer statistics. CA Cancer J Clin 2002;55:74-108.
3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nature 2007;7:778-790.
4. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008;26:5589-5595.
5. Kim HS, Park K, Jun HJ, et al. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology 2009;76:239-246.
6. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-1093.
7. Zell JA, Ou SH, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005;23:8396-8405.
8. Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small-cell lung cancer histologies. J Thorac Oncol 2009;4:1201-1211.
9. Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never- smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-351.
10. Subramanian J, Govindan R. Lung cancer in never-smokers: a review. J Clin Oncol 2007;25:561-570.
11. Kenfield SA, Wei EK, Stampfer MJ, et al. Comparison of aspects of smoking among four histological types of lung cancer. Tob Control 2008;17:198-204.
12. Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest 2001;120:1577-1583.
13. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007;36:1048-1059.
14. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: gefitinib (ZD1839, Iressa) tablets. Clin Cancer Res 204;10:1212-1218.
15. Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10:461-466.
16. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-855.
17. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
18. Liu W, Innicenti F, Chen P, et al. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-1012.
19. Dubey S, Stephenson P, Levy DE, et al. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J Thorac Oncol 2006;1:406-412.
20. Park MJ, Lee J, Hong JY, et al. Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 2009;115:1518-1530.
21. Florescu M, Hasan B, Seymour L, et al. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21. J Thorac Oncol 2008;3:590-598. (Pubitemid 351787301)
22. Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small-cell lung cancer (NSCLC): a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol In press.